Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats

Diabetes Research and Clinical Practice

Volumn 43, Issue 2, 1999, Pages 81-89

  Degenhardt, Thorsten P ^a,d   Fu, Min Xin ^a   Voss, Edgar ^c   Reiff, Klaus ^c   Neidlein, Richard ^d   Strein, Klaus ^c   Thorpe, Suzanne R ^a   Baynes, John W ^a,b   Reiter, Rudolf ^c  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Advanced glycation end products (AGE); Albuminuria; Aminoguanidine; Collagen; N( ) (carboxymethyl)lysine; Pentosidine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINOGUANIDINE; COLLAGEN; HEMOGLOBIN; HEMOGLOBIN A1C; LYSINE DERIVATIVE; PENTOSIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEINURIA; RAT; SKIN; STREPTOZOCIN DIABETES;

EID: 0032892660     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00121-1     Document Type: Article

References (51)

1. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J. Lab. Clin. Med. 124:1994;19-30.
2. Bucala R., Vlassara H. Advanced glycosylation endproducts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif. 13:1995;160-170.
3. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J.-L., Stern D. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14:1994;1521-1528.
4. Brownlee M., Vlassara H., Kooney T., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 232:1986;1629-1632.
5. Fu M.X., Knecht K.J., Thorpe S.R., Baynes J.W. Role of oxygen in crosslinking and chemical modification of collagen by glucose. Diabetes. 41:1992;42-48.
6. Fu M.X., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S.R., Baynes J.W. Glycation, glycoxidation and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 43:1994;676-683.
7. Itakura M., Yoshikawa H., Bannai C., Kato M., Kunika K., Kawakami Y., Yamaoka T., Yamashita K. Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci. 49:1991;889-897.
8. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes. 40:1991;1328-1334.
9. Edelstein D., Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia. 35:1992;96-97.
10. Hammes H.P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA. 88:1991;11555-11558.
11. Hammes H.P., Brownlee M., Edelstein D., Saleck M., Martin S., Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 37:1994;32-35.
12. Kihara M., Schmelzer J.D., Poduslo J.F., Curran G.L., Nickander K.K., Low P.A. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. USA. 88:1991;6107-6111.
13. Yagihashi S., Kamijo M., Baba M., Yagihashi N., Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 41:1992;47-52.
14. Cameron N.E., Cotter M.A., Dines K., Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia. 35:1992;946-950.
15. Huijberts M.S., Wolffenbuttel B.H., Boudier H.A., Crijns F.R., Kruseman A.C., Poitevin P., Levy B.I. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J. Clin. Invest. 92:1993;1407-1411.
16. Yu H.P., Zou D.M. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia. 40:1997;1243-1250.
17. Tilton R.G., Chang K., Hasan K.S., Smith S.R., Petrash J.M., Misko T.P., Moore W.M., Currie M.G., Corbett J.A., McDaniel M.L., Williamson J.R. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes. 42:1993;221-232.
18. Corbett J.A., Tilton R.G., Chang K., Hasan K.S., Ido Y., Wang J.L., Sweetland M.A., Lancaster J.R., Williamson J.R., McDaniel M.L. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
19. Picard S., Parthasarathy S., Fruebis J., Witztum J.L. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc. Natl. Acad. Sci. USA. 89:1992;6876-6880.
20. Requena J.R., Vidal P., Cabezas-Cerrato J. Aminoguanidine inhibits the modification of proteins by lipid peroxidation derived aldehydes: a possible antiatherogenic agent. Diabetes Res. 20:1992;43-49.
21. Scaccini C., Chiesa G., Jialal I. A critical assessment of the effects of aminoguanidine and ascorbate on the oxidative modification of LDL: evidence for interference with some assays of lipoprotein oxidation by aminoguanidine. J. Lipid Res. 35:1994;1085-1092.
22. Philis-Tsimikas A., Parthasarathy S., Picard S., Palinski W., Witztum J.L. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler. Thromb. Vasc. Biol. 15:1995;367-376.
23. Nyengaard J.R., Chang K., Berhorst S., Reiser K.M., Williamson J.R., Tilton R.G. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes. 46:1997;94-106.
24. Soulis T., Thallas V., Youssef S., Gilbert R.E., McWilliam B.G., Murray-McIntosh R.P., Cooper M.E. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia. 40:1997;619-628.
25. Sell D.R., Monnier V.M. Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J. Biol. Chem. 264:1989;21597-21602.
26. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during non-enzymatic browning of proteins by glucose. J. Biol. Chem. 266:1991;1654-1660.
27. ε-(carboxymethyl)lysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 261:1986;4889-4894.
28. Dyer D.G., Dunn J.A., Thorpe S.R., Bailie K.E., Lyons T.J., McCance D.R., Baynes J.W. Accumulation of Maillard reaction products in diabetes and aging. J. Clin. Invest. 91:1993;2463-2469.
29. Beaven M.A., Gordon J.W., Jacobsen S., Severs W.B. A specific and sensitive assay for aminoguanidine: its implication to a study of the disposition of aminoguanidine in animal tissues. J. Pharmacol. Exp. Ther. 165:1969;14-22.
30. ε-(carboxymethyl)-hydroxylysine in human skin collagen. Biochemistry. 30:1991;1205-1210.
31. Heinzel G., Woloszczak R., Thomann P. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. 1993;Fischer, Stuttgart.
32. Degenhardt T.P. Pharmakokinetik an ausgewahlten antidiabetisch wirksamen Substanzen und Untersuchungen zu Hemmstoffen der nichtenzymatischen, Glykosylierung. 1995;Universität Heidelberg, Heidelberg. PhD thesis.
33. ε-(carboxymethyl)lysine (CML), is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271:1996;9982-9986.
34. Oxlund H., Andreassen T.T. Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. Diabetologia. 35:1992;19-25.
35. Brennan M. Changes in solubility, non-enzymatic glycation, and fluorescence of collagen in tail tendons from diabetic rats. J. Biol. Chem. 264:1989;20947-20952.
36. Brennan M. Changes in the cross-linking of collagen from rat tail tendons due to diabetes. J. Biol. Chem. 264:1989;20953-20960.
37. Sell D.R., Lapolla A., Odetti P., Fogarty J., Monnier V.M. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes. 41:1992;1286-1292.
38. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 91:1993;2470-2478.
39. Wells-Knecht M.C., Thorpe S.R., Baynes J.W. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry. 34:1995;15134-15141.
40. Edelstein D., Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:1992;26-29.
41. Lyons T.J., Bailie K.E., Dyer D.G., Dunn J.A., Baynes J.W. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J. Clin. Invest. 87:1991;1910-1915.
42. Glomb M.A., Monnier V.M. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 270:1995;10017-10026.
43. Khalifah R.G., Todd P., Booth A.A., Yang S.X., Mott J.D., Hudson B.G. Kinetics of non-enzymatic glycation of ribonuclease a leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. Biochemistry. 35:1996;4645-4654.
44. Booth A.A., Khalifah R.G., Hudson B.G. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem. Biophys. Res. Commun. 220:1996;113-119.
45. Hui J.Y., Taylor S.L. Inhibition of in vivo histamine metabolism in rats by foodborne and pharmacologic inhibitors of diamine oxidase, histamine N-methyltransferase, and monoamine oxidase. Toxicol. Appl. Pharmacol. 81:1985;241-249.
46. Tang S.-S., Chichester C.O., Kagan H.M. Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors. Connect. Tissue Res. 19:1989;93-103.
47. Seyer-Hansen M., Andreassen T.T., Oxlund H., Jorgensen P.H. The influence of aminoguanidine on borohydride reducible collagen cross-links and wound strength. Connect. Tissue Res. 26:1991;181-186.
48. MacAllister R.J., Whitley G.S., Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int. 45:1994;737-742.
49. Wolff D.J., Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch. Biochem. Biophys. 316:1995;290-301.
50. Ou P., Wolff S.P. Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem. Pharmacol. 46:1993;1139-1144.
51. Okada M., Ayabe Y. Effects of aminoguanidine and pyridoxal phosphate on glycation reaction of aspartate aminotransferases and serum albumin. J. Nutr. Sci. Vitaminol. 41:1995;43-50.